References of "Beckers, Albert"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAn unusual pituitary pathology
Petrossians, Patrick ULg; Delvenne, Philippe ULg; Flandroy, P. et al

in Journal of Clinical Endocrinology and Metabolism (1998), 83(10), 3454-3458

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailThe burden of illness of hypopituitary adults with growth hormone deficiency.
Hakkaart-van Roijen, L.; Beckers, Albert ULg; Stevenaert, Achille ULg et al

in PharmacoEconomics (1998), 14(4), 395-403

Objective: The negative metabolic and psychosocial consequences of growth hormone deficiency (GHD) in adults are now well established. In the present study, an attempt was made to quantify the burden of ... [more ▼]

Objective: The negative metabolic and psychosocial consequences of growth hormone deficiency (GHD) in adults are now well established. In the present study, an attempt was made to quantify the burden of illness, in terms of lost productivity and increased medical consumption, associated with hypopituitarism and untreated GHD. Design and Setting: The study population consisted of 129 Belgian adults with untreated GHD associated with hypopituitarism after pituitary surgery. The Short-Form 36 Health Survey (SF-36) was used to assess health status, and the Health and Labour Questionnaire was used to measure production losses and labour performance. Data on medical consumption were also collected. Main Outcome Measures and Results: Hypopituitary patients reported a lower health status than that of the general population in all but two dimensions of the SF-36 (pain and physical functioning). Nearly 11% of the patients reported being incapacitated for paid employment due to health problems, compared with 4.8% of the general Belgian population. Patients in paid employment reported a mean of 19.8 days of sickness leave per year, which is twice that in the general population. The annual number of visits to general practitioners and specialists was also higher in the patients (9.6 and 6.5 visits, respectively, for the patients compared with corresponding figures of 2.1 and 1.5 for the general Belgian population). The average annual number of days spent in hospital was 3.5 for the patients compared with 2.3 in the general population. The annual healthcare costs and costs due to production losses calculated for hypopituitary patients who had received pituitary surgery amounted to 135 024 Belgian francs (BeF) or $US4340 (1995 values). This compares with the mean annual cost per person for the Belgian population as a whole of BeF68 569 or $US2204. Conclusions: Hypopituitary patients with untreated GHD therefore have a higher cost to society in terms of lost production and medical consumption than the average Belgian population. [less ▲]

Detailed reference viewed: 28 (0 ULg)
See detailAcromegalie : Consult
Beckers, Albert ULg; Stevenaert, Achille ULg

in Medical News (1998), 49

Detailed reference viewed: 10 (0 ULg)
See detailAcromégalie : Consultation
Beckers, Albert ULg; Stevenaert, Achille ULg

in Medical News (1998), 49

Detailed reference viewed: 16 (0 ULg)
See detailOverview of octreotide presurgical treatment of acromegaly
Beckers, Albert ULg

Scientific conference (1998, May)

Detailed reference viewed: 8 (0 ULg)
See detailLes néoplasies endocriniennes multiples
Beckers, Albert ULg

Scientific conference (1998, March 05)

Detailed reference viewed: 9 (0 ULg)
See detailL'exploration de l'axe hypotalamo-hypophysaire
Beckers, Albert ULg

Scientific conference (1998, February 21)

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailCabergoline in the treatment of acromegaly: a study in 64 patients.
Abs, Roger; Verhelst, Johan; Maiter, Dominique et al

in Journal of Clinical Endocrinology and Metabolism (1998), 83(2), 374-8

Cabergoline is a new, long acting, dopamine agonist that is more effective and better tolerated than bromocriptine in patients with hyperprolactinemia. Because dopamine agonists still have a place in the ... [more ▼]

Cabergoline is a new, long acting, dopamine agonist that is more effective and better tolerated than bromocriptine in patients with hyperprolactinemia. Because dopamine agonists still have a place in the medical management of acromegaly, cabergoline might be a useful treatment. We, therefore, evaluated the effect of long term administration of cabergoline in a large group of unselected acromegalic patients. Sixty-four patients were included in a multicenter, prospective, open labeled study. A subgroup of 16 patients had GH-/PRL-cosecreting pituitary adenomas. Cabergoline was started at a dose of 1.0 mg/week and was gradually increased until normalization of plasma insulin-like growth factor I (IGF-I) levels, occurrence of unacceptable side-effects, or a maximal weekly dose of 3.5 mg (7.0 mg in 1 case) was reached. Treatment with cabergoline suppressed plasma IGF-I below 300 micrograms/L in 39% of cases and between 300-450 micrograms/L in another 28%. With pretreatment plasma IGF-I concentrations less than 750 micrograms/L, a suppression of IGF-I below 300 micrograms/L was obtained in 53% of cases, and a suppression between 300-450 micrograms/L was obtained in another 32%. By contrast, with pretreatment plasma IGF-I concentrations above 750 micrograms/L, only 17% of cases showed a suppression of IGF-I below 300 micrograms/L, and there was IGF-I suppression between 300-450 micrograms/L in another 21%. In GH-/PRL-cosecreting adenomas, 50% of cases suppressed plasma IGF-I levels below 300 micrograms/L, and another 31% did so between 300-450 micrograms/L, in contrast to only 35% and 27%, respectively in GH-secreting adenomas. Similar results were obtained concerning the secretion of GH. Tumor shrinkage was demonstrated in 13 of 21 patients, with a mass reduction by more than half in 5 GH-/PRL-cosecreting adenomas. Except for slight gastrointestinal discomfort and orthostatic hypotension in a few patients at the beginning of therapy, cabergoline treatment was well tolerated. Only 2 patients stopped medication because of nausea. The weekly dose of cabergoline ranged between 1.0-1.75 mg. A further increase in the dose was only effective in 1 GH-/PRL-cosecreting adenoma. The results of this study suggest that cabergoline is an effective, well tolerated therapy that should be considered in the management of acromegaly, especially if the pituitary adenoma cosecretes GH and PRL or if pretreatment plasma IGF-I levels are below 750 micrograms/L. [less ▲]

Detailed reference viewed: 55 (2 ULg)
See detailMultiple Endocrine Neoplasia 1 : From the clinic to the gene
Beckers, Albert ULg

Scientific conference (1998, January 30)

Detailed reference viewed: 5 (0 ULg)
See detailMutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type I and related diseases
Poncin, Jacques ULg; Abs, R.; Velkeniers, B. et al

in IV european Congress of Endocrinology - Abstract book (1998)

Detailed reference viewed: 4 (0 ULg)
See detailOverview of presurgical somatostatin analog treatment in acromegaly
Beckers, Albert ULg; Stevenaert, Achille ULg

in IV european Congress of Endocrinology - Abstract book (1998)

Detailed reference viewed: 6 (0 ULg)
See detailMutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type I and related diseases
Poncin, Jacques ULg; Abs, R.; Velkeniers, B. et al

in 5th Euroregional Oncology meeting - abstract book (1998)

Detailed reference viewed: 6 (0 ULg)
See detailThe spectrum of MEN1 gene mutations in Belgian patients with MEN1 and related diseases
Poncin, Jacques ULg; Abs, R.; Velkeniers, B. et al

in The 5th International Pituitary congress - Abstract book (1998)

Detailed reference viewed: 5 (0 ULg)
See detailInsuffisance hypophysaire et amaurose subaiguës causées par une pseudotumeur inflammatoire extensive du sinus sphénoïde
Hansen, Isabelle ULg; Petrossians, Patrick ULg; Flandroy, Pierre et al

in XVI Congrès de la Société Française d'Endocrinologie - Abstract book (1998)

Detailed reference viewed: 53 (0 ULg)
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in 5th International Pituitary congress - abstract book (1998)

Detailed reference viewed: 6 (0 ULg)
See detailThe spectrum of MEN1 gene mutations in Belgian patients with MEN1 and related diseases
Poncin, Jacques ULg; Abs, R.; Velkeniers, B. et al

in 80th Annual Meeting of the Endocrine society - Abstract book (1998)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailMutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism.
Teh, B. T.; Kytola, S.; Farnebo, F. et al

in Journal of Clinical Endocrinology and Metabolism (1998), 83(8), 2621-2626

Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominant disease characterized by neoplasia of the parathyroid glands, the endocrine pancreas, and the anterior pituitary gland. In addition ... [more ▼]

Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominant disease characterized by neoplasia of the parathyroid glands, the endocrine pancreas, and the anterior pituitary gland. In addition, families with isolated endocrine neoplasia, notably familial isolated hyperparathyroidism (FIHP) and familial acromegaly, have also been reported. However, whether these families constitute MEN 1 variants or separate entities remains speculative as the genetic bases for these diseases are unclear. The gene for MEN 1 has recently been cloned and characterized. Using single strand conformation analysis (SSCA) and sequencing, we performed mutation analysis in: a) a total of 55 MEN 1 families from 7 countries, b) 13 isolated MEN 1 cases without family history of the disease, c) 8 acromegaly families, and d) 4 FIHP families. Mutations were identified in 27 MEN 1 families and 9 isolated cases. The 22 different mutations spread across most of the 9 translated exons and included frameshift (11), nonsense (6), splice (2), missense mutations (2), and in-frame deletions (1). Among the 19 Finnish MEN 1 probands, a 1466del12 mutation was identified in 6 families with identical 11q13 haplotypes and in 2 isolated cases indicating a common founder. One frameshift mutation caused by 359del4 (GTCT) was found in 1 isolated case and 4 kindreds of different origin and haplotypes; this mutation therefore represents a common "warm" spot in the MEN1 gene. By analyzing the DNA of the parents of an isolated case one mutation was confirmed to be de novo. No mutation was found in any of the acromegaly and small FIHP families, suggesting that genetic defects other than the MEN1 gene might be involved and that additional such families need to be analyzed. [less ▲]

Detailed reference viewed: 89 (5 ULg)
Peer Reviewed
See detailAspects genetiques du male 46, XX.
Marquet, F.; Beckers, Albert ULg; Verloes, Alain ULg

in Revue Médicale de Liège (1998), 53(12), 738-740

The XX males represent a proportion of 1/25 of all patients suffering of the Klinefelter syndrome. From a clinical and endocrinological point of view, they exhibit a hypogonadotropic hypogonadism ... [more ▼]

The XX males represent a proportion of 1/25 of all patients suffering of the Klinefelter syndrome. From a clinical and endocrinological point of view, they exhibit a hypogonadotropic hypogonadism. Isolated cases are rare and familial forms are exceptional. The XX males may be divided in 3 subgroups: 46, XX males with the SRY gene; 46, XX males without the SRY gene and XX/XY mosaics. [less ▲]

Detailed reference viewed: 60 (5 ULg)